Boryun-Roche target anticancer market together
Boryung Pharm and Roche will target the anticancer market with hands together.
According to the industry concerned on the 18th, Boryung Pharm was known to jointly sell the Roche Korea’s non-small cell lung cancer therapy, Tarceva(generic name: erlotinib).
The agreement between the two compani...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
